Gilead Sciences, Inc. : Gilead's Idelalisib Significantly Reduces Rate of ... 4-traders (press release) (BUSINESS WIRE)--Nov. 18, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Phase 3 study (Study 116) evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia (CLL) patients ... |
